Scarica l'app Stockscreener
6.79
1.88%
-0.13
Dopo l'orario di chiusura:
6.75
-0.04
-0.59%
Corvus Pharmaceuticals Inc Borsa (CRVS) Ultime notizie
Will Corvus Pharmaceuticals Inc. stock split attract more investors2025 Bull vs Bear & AI Optimized Trading Strategy Guides - ulpravda.ru
Will Corvus Pharmaceuticals Inc. stock gain from lower inflation2025 Retail Activity & Step-by-Step Swing Trade Plans - ulpravda.ru
Is Corvus Pharmaceuticals Inc. stock ready for breakoutIndex Update & Risk Controlled Swing Alerts - ulpravda.ru
Can Corvus Pharmaceuticals Inc. stock reach $100 price targetJuly 2025 Big Picture & Fast Gaining Stock Strategy Reports - ulpravda.ru
Will Corvus Pharmaceuticals Inc. stock outperform international peers2025 AllTime Highs & AI Powered Market Entry Strategies - ulpravda.ru
Is Corvus Pharmaceuticals Inc. stock a good choice for value investorsJuly 2025 Update & Accurate Intraday Trade Tips - ulpravda.ru
How supply chain issues affect Corvus Pharmaceuticals Inc. stockMarket Movement Recap & Capital Efficiency Focused Strategies - ulpravda.ru
Should I hold or sell Corvus Pharmaceuticals Inc. stock in 20252025 Key Lessons & Reliable Entry Point Trade Alerts - ulpravda.ru
Hedge Fund Moves: Is Corvus Pharmaceuticals Inc stock ready for breakout2025 Winners & Losers & Technical Pattern Alert System - moha.gov.vn
Can Corvus Pharmaceuticals Inc. stock beat analyst upgradesMarket Volume Summary & Technical Buy Zone Confirmation - ulpravda.ru
Corvus Pharmaceuticals to announce atopic dermatitis trial results in January By Investing.com - Investing.com Nigeria
Both Retail Investors Who Control a Good Portion of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Along With Institutions Must Be Dismayed After Last Week's 9.3% Decrease - 富途牛牛
Both retail investors who control a good portion of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) along with institutions must be dismayed after last week's 9.3% decrease - simplywall.st
Corvus Pharmaceuticals to announce atopic dermatitis trial results in January - Investing.com
Corvus Pharmaceuticals Confirms Plans to Announce Results - GlobeNewswire
Corvus Pharmaceuticals (NASDAQ:CRVS) Stock Price Down 6.5%Should You Sell? - MarketBeat
Is Corvus Pharmaceuticals Inc a good long term investmentInsider Trading Activity & Free Real-Time Trading Signals - earlytimes.in
How strong is Corvus Pharmaceuticals Inc. stock balance sheetRetail Trading Trends & Free Trading Signals to Sharpen Your Edge - bollywoodhelpline.com
Corvus Pharmaceuticals (NASDAQ:CRVS) Shares Up 3.5% – Still a Buy? - Defense World
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Corvus Pharmaceuticals (NASDAQ:CRVS) Shares Up 3.5%Here's Why - MarketBeat
Corvus Pharmaceuticals, Inc.(NasdaqGM:CRVS) added to S&P Biotechnology Select Industry Index - MarketScreener
IPO Launch: Will Corvus Pharmaceuticals Inc. stock split attract more investors2025 Earnings Surprises & Reliable Intraday Trade Plans - moha.gov.vn
Aug Macro: Why Corvus Pharmaceuticals Inc. stock appeals to dividend seekersJuly 2025 Opening Moves & Weekly Stock Breakout Alerts - Улправда
Hedge Fund Moves: How strong is Corvus Pharmaceuticals Inc. stock balance sheet2025 Sector Review & Momentum Based Trading Signals - ulpravda.ru
- ulpravda.ru
Corvus Pharmaceuticals Earnings Notes - Trefis
Corvus Pharmaceuticals stock awaits key January 2026 trial data By Investing.com - Investing.com Canada
What is Corvus Pharmaceuticals Inc (CRVS) Stock Return on Shareholders’ Capital? - setenews.com
Eczema Clinical Trial Pipeline Accelerates as 100+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight - The Manila Times
Corvus Pharmaceuticals (NASDAQ:CRVS) Trading 7.1% HigherWhat's Next? - MarketBeat
Corvus Pharmaceuticals Reports Promising Phase 1 Data for Soquelitinib in Relapsed/Refractory T Cell Lymphoma at ASH Annual Meeting - Quiver Quantitative
Corvus Pharmaceuticals Presents Final Data from Soquelitinib Phase 1/1b T Cell Lymphoma Trial - The Manila Times
Corvus Pharma (CRVS) Stock Analysis Report | Financials & Insights - Benzinga
Corvus Pharmaceuticals (NASDAQ:CRVS) Sets New 12-Month HighHere's What Happened - MarketBeat
You might want to take a look at Corvus Pharmaceuticals Inc (CRVS) now - setenews.com
Will Corvus Pharmaceuticals Inc. stock split again soonMarket Performance Report & Growth Focused Investment Plans - Newser
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Receives Average Rating of “Moderate Buy” from Analysts - Defense World
Corvus Pharmaceuticals (NASDAQ:CRVS) Stock Price Down 8%Here's What Happened - MarketBeat
Here's Why We're Not Too Worried About Corvus Pharmaceuticals' (NASDAQ:CRVS) Cash Burn Situation - Yahoo Finance
Is Corvus Pharmaceuticals Inc. stock a buy before product launchesDividend Hike & Intraday High Probability Alerts - Newser
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Perhaps timely catching Corvus Pharmaceuticals Inc (CRVS) would be a good idea - Setenews
Foresite Capital Management VI LLC Boosts Position in Corvus Pharmaceuticals, Inc. $CRVS - MarketBeat
Corvus Pharmaceuticals: Trial Momentum Keeps Stock In Focus - RTTNews
What risks investors should watch in Corvus Pharmaceuticals Inc. stockWeekly Trend Summary & Weekly Watchlist for Consistent Profits - newser.com
Will Corvus Pharmaceuticals Inc. stock reach Wall Street targetsPortfolio Growth Summary & Technical Buy Zone Confirmation - newser.com
0.90%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):